Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ceftolozane/tazobactam - Merck Sharp & Dohme

Drug Profile

Ceftolozane/tazobactam - Merck Sharp & Dohme

Alternative Names: CXA-101/tazobactam; CXA-201; MK-7625A; Tazobactam/ceftolozane; Tazobactam/CXA-101; Zerbaxa

Latest Information Update: 30 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma
  • Developer M. D. Anderson Cancer Center; Merck Sharp & Dohme
  • Class 2 ring heterocyclic compounds; Anti-infectives; Anti-inflammatories; Antibacterials; Cephalosporins; Small molecules; Sulfones; Triazoles
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections
  • Registered Pyelonephritis
  • Phase II Bacterial infections

Most Recent Events

  • 09 Sep 2019 Merck Sharp & Dohme plans a phase-I trial for Nosocomial pneumonia (In neonates, In infants, In children, In adolescents) in Russia, Ukraine, USA (IV) (EudraCT2018-004704-19)
  • 25 Jul 2019 Committee for Medicinal Products for Human Use (CHMP) adopts positive opinion for Nosocomial pneumonia including hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia
  • 04 Jun 2019 Launched for Nosocomial pneumonia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top